IRF7
骨转移
转移
癌症研究
先天免疫系统
免疫系统
干扰素
生物
基因沉默
免疫监视
免疫学
癌症
医学
内科学
基因
生物化学
作者
Bradley N. Bidwell,Clare Y. Slaney,Nimali P. Withana,Samuel C. Forster,Yuan Cao,Sherene Loi,Daniel M. Andrews,Thomas Mikeska,Niamh E. Mangan,Shamith A. Samarajiwa,Nicole A. de Weerd,Jodee Gould,Pedram Argani,Andreas Möller,Mark J. Smyth,Robin L. Anderson,Paul J. Hertzog,Belinda S. Parker
出处
期刊:Nature Medicine
[Springer Nature]
日期:2012-07-22
卷期号:18 (8): 1224-1231
被引量:392
摘要
Breast cancer metastasis is a key determinant of long-term patient survival. By comparing the transcriptomes of primary and metastatic tumor cells in a mouse model of spontaneous bone metastasis, we found that a substantial number of genes suppressed in bone metastases are targets of the interferon regulatory factor Irf7. Restoration of Irf7 in tumor cells or administration of interferon led to reduced bone metastases and prolonged survival time. In mice deficient in the interferon (IFN) receptor or in natural killer (NK) and CD8(+) T cell responses, metastasis was accelerated, indicating that Irf7-driven suppression of metastasis was reliant on IFN signaling to host immune cells. We confirmed the clinical relevance of these findings in over 800 patients in which high expression of Irf7-regulated genes in primary tumors was associated with prolonged bone metastasis-free survival. This gene signature may identify patients that could benefit from IFN-based therapies. Thus, we have identified an innate immune pathway intrinsic to breast cancer cells, the suppression of which restricts immunosurveillance to enable metastasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI